Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy
Article first published online: 5 NOV 2012
© 2012 John Wiley & Sons Ltd
Influenza and Other Respiratory Viruses
Volume 7, Issue 5, pages 815–826, September 2013
How to Cite
Fox, C. B., Barnes V, L., Evers, T., Chesko, J. D., Vedvick, T. S., Coler, R. N., Reed, S. G. and Baldwin, S. L. (2013), Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy. Influenza and Other Respiratory Viruses, 7: 815–826. doi: 10.1111/irv.12031
- Issue published online: 21 AUG 2013
- Article first published online: 5 NOV 2012
- Accepted 14 September 2012. Published Online 5 November 2012.
- 6Data Analysis for Chemistry. New York: Oxford University Press, 2006., .
- 8U.S. Food and Drug Administration. Inactive Ingredient Search for Approved Drug Products [database on the Internet]. U.S. Food and Drug Administration. Available at http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm (Accessed August 8, 2012).
- 16Principles in the development of intravenous lipid emulsions; in Wasan KM (ed.): Role of Lipid Excipients in Modifying Oral and Parenteral Drug Delivery. Hoboken, NJ: John Wiley & Sons Inc., 2006; 88–123., .
- 18Sasol. Miglyol Product Information. Available at http://www.sasoltechdata.com/tds/miglyols.pdf (Accessed 17 December 2007).
- 19Available at http://www.chemspider.com (Accessed 8 August 2012).